Skip to main content
Premium Trial:

Request an Annual Quote

Hematogenix FDA Approved PD-L1 Companion Diagnostic Test

Hematogenix Laboratory Services is offering two US Food and Drug Administration approved PD-L1 companion diagnostic assays: PD-L1 IHC 22C3 pharmDx for Keytruda and PD-L1 IHC 28-8 pharmDx. Dako, an Agilent company, developed PD-L1 IHC 22C3 pharmDx Keytruda in partnership with Merck. Keytruda is approved by the FDA to treat patients with metastatic non-small cell lung cancer whose tumors express PD-L1 and have disease progression on or after platinum-containing chemotherapy. PD-L1 IHC 28-8 pharmDx, also developed by Dako, was approved as a companion diagnostic for Bristol-Myers Squibb's Opdivo, to detect PD-L1 protein expression levels and to help physicians determine which patients may benefit most from treatment with the therapy. Both kits are available through Dako.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.